However, not all nucleoside reverse transcriptase inhibitors have equivalent effects [4, 5] . In a randomized controlled trial comparing efavirenz (EFV) in combination with tenofovir disoproxil fumarate (TDF) or zidovudine (AZT), the AZT arm showed greater dyslipidaemia, and lipoatrophy [6] . Thymidine analogues, such as AZT, are believed to interfere with mitochondrial DNA (mtDNA) polymerization [7] , but also affect mitochondrial function and adipocyte metabolism through other mechanisms, such as interference with the transcription of mitochondrial proteins involved with the respiratory chain [8, 9] .
Nucleoside analogues, used as a component of combination antiretroviral therapy for HIV infection, have been implicated in the accompanying lipoatrophy [1] , abnormal serum lipids [1, 2] and insulin resistance [3] . However, not all nucleoside reverse transcriptase inhibitors have equivalent effects [4, 5] . In a randomized controlled trial comparing efavirenz (EFV) in combination with tenofovir disoproxil fumarate (TDF) or zidovudine (AZT), the AZT arm showed greater dyslipidaemia, and lipoatrophy [6] . Thymidine analogues, such as AZT, are believed to interfere with mitochondrial DNA (mtDNA) polymerization [7] , but also affect mitochondrial function and adipocyte metabolism through other mechanisms, such as interference with the transcription of mitochondrial proteins involved with the respiratory chain [8, 9] .
We investigated the effects of 6 months of treatment with TDF or AZT, taken with EFV in combination with lamivudine (3TC) or emtricitabine (FTC), respectively, on body fat distribution, plasma postheparin hepatic and lipoprotein lipase (LPL) activity, serum adipocytokines and insulin resistance, and the expression of a number of key genes controlling fatty acid and glucose metabolism, adipocyte Introduction differentiation and mitochondrial energy metabolism in subcutaneous adipocytes.
Methods
The study obtained ethical committee approval from the South Birmingham Research Ethics Committee, Birmingham, UK. Patients (n=32) naive to antiretroviral therapy and eligible for treatment according to the British HIV Association guidelines were recruited from the HIV clinic. All patients signed an informed consent form to participate in the study. Where necessary, interpreters were provided to explain the study and answer any questions before obtaining consent. Patients were randomized to receive one of the following therapies: AZT+3TC (as proprietary preparation Combivir) +EFV (twice-daily dosage; n=15 patients) or TDF+FTC (as proprietary preparation Truvada) +EFV (once-daily dosage; n=17 patients). Controls (n=15) were HIV-antibody-negative participants, matched for age, ethnicity and gender. Demographic details of the patients and controls are given in Table 1 .
Exclusion criteria included fasting glucose >6.1 mmol/l, weekly alcohol intake >28 units (male) or 21 units (female), taking lipid-lowering drugs, glucocorticoids, or any drugs that affect lipid metabolism (patients on lipid-lowering drugs were asked to discontinue them for at least 6 weeks), hypothyroidism, creatinine >150 mmol/l and alanine aminotransferase or aspartate aminotransferase >5× the upper limit of normal, anaemia, >10% loss in body weight in the preceding 6 months, hepatitis B and C and any AIDSdefining disease. Taking oral contraceptives was not an exclusion criterion.
All participants had a full history taken, including alcohol intake, concomitant medication and family history of cardiovascular disease and diabetes. Before recruitment, a fasting blood sample was taken to carry out a lipid profile, liver function test, thyroid function test, urea and electrolytes, blood glucose, full blood count, CD4 + T-cell count and viral load measurement. Patients were tested before and 5-7 months following the initiation of therapy. On each visit they were admitted in the morning to the Wellcome Trust Research Facility at Queen Elizabeth Hospital (Birmingham, UK) having fasted from 9 pm the previous evening. Blood pressure, body mass index (BMI) and waist-to-hip ratio were measured. Fasting blood samples were taken for a lipid profile, liver function tests and a full blood count. Levels of lipoprotein(a), non-esterified fatty acid, glucose, insulin, adiponectin, leptin, urea, creatinine, electrolytes (including chloride and bicarbonate) were also measured. Insulin resistance and β-cell insulin secretion was calculated from fasting insulin and glucose using the homeostasis model of assessment (HOMA) for insulin resistance (HOMA-IR) and β-cell function (HOMA-B), respectively [10] .
Participants underwent a whole-body DEXA scan for body fat distribution and a single slice CT scan at L4 to measure subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT). DEXA scan results are expressed as a ratio of peripheral fat (arms and legs) or trunk fat to lean body mass (LBM). Three subcutaneous fat biopsies from the iliac crest were performed through a 1 cm incision under local anaesthesia and the samples snap frozen and stored at -80°C until assayed. At the end of the study period, participants were given a single bolus of 50 IU heparin/kg body weight. Blood was taken in heparinised tubes on ice for estimation of hepatic and LPL before and 15 min following the heparin injection. Following total RNA extraction from the fat biopsy samples and preparation of complimentary DNA, gene expression was profiled using real-time PCR and quantified relative to an internal housekeeping gene (18S).
RNA extraction and reverse transcription
Total RNA extraction was carried out using the RNeasy Lipid Tissue Kit (QIAGEN, Ltd, Crawley, UK), and was quantified using a spectrophotometer (Nanodrop ND-1000; Labtech, Ringmer, UK), measuring at an absorbance of 260 nm. All RNA extraction was followed by a DNase digestion step to remove contaminating genomic DNA (DNase I Kit, Sigma-Aldrich Company Ltd, Dorset, UK). A quantity of 200 ng of RNA from each sample was reverse transcribed using SuperScript III reverse transcriptase (Invitrogen Ltd, Paisley, UK), and random primers in 20 µl reaction volumes, according to the manufacturer's instructions, and heated in a thermocycler (Bio-Rad Laboratories Ltd, Hertfordshire, UK) at 50°C for 1 h, then heated to 70°C for 15 min to terminate the reaction.
Real-time PCR
Messenger RNA (mRNA) levels of target genes were determined using an ABI 7500 sequence detection system (Perkin-Elmer Applied Biosystems, Warrington, UK). Reactions were performed in 25 µl volumes on 96-well plates in reaction buffer containing 2× TaqMan ® Universal PCR Master mix (Applied Biosystems, Foster City, CA, USA). All primers and probes were supplied by Assays-on-Demand™ (Applied Biosystems). Measurements were carried out in triplicate. All reactions were normalized against the housekeeping gene, 18S, provided as a pre-optimized control probe (Applera, Cheshire, UK). All target genes were labelled with FAM™ and the housekeeping gene with VIC ® (TaqMan ® ; Applied Biosystems). The reaction conditions were as follows: 50°C for 2 min, 95°C for 10 min, then 44 cycles of 95°C for 15 s and 60°C for 1 min.
Data were obtained as cycle threshold (ct) values (that is, the cycle number at which logarithmic PCR plots cross a calculated threshold line) and used to determine ∆ct values (∆ct =[ct of the target gene] -[ct of the housekeeping gene]). Data were expressed as arbitrary units (AUs) using the following transformation: expression =10 4 •(2 -∆ct ) AU or using fold change relative to specific control, where fold-change =2 -difference in ∆ct Genes profiled included those involved in adipocyte glucocorticoid and lipid metabolism, adipocyte differentiation and mitochondrial respiratory function.
Genes involved in glucocorticoid generation, essential for adipocyte differentiation were 11β-hydroxysteroid dehydrogenase type-1 (11βHSD-1), which regenerates the active glucocorticoid cortisol from inactive cortisone [11] ; hexose 6-phosphate dehydrogenase (H6PDH), which generates the cofactor NADPH for 11βHSD-1 and is essential for 11βHSD-1 oxo-reductase activity [12] ; and glucocorticoid receptor (GR)-α.
Genes involved in adipocyte differentiation and lipid metabolism were peroxisome proliferator-activated receptor (PPAR)-γ, which induces the differentiation of pre-adipocytes and stimulates fatty acid flux, triglyceride storage, and insulin sensitivity; fatty acid synthase (FAS); fatty acid binding protein-4 (FABP-4); LPL; hormone-sensitive lipase (HSL); glucose receptor-4 (GLUT-4), the predominant isoform of the glucose transporter that mediates insulin-mediated uptake of glucose; acetyl coenzyme A carboxylase (ACC)-1, the rate-limiting enzyme controlling lipogenesis; and ACC-2, a key negative regulator of β-oxidation through malonyl coenzyme A (CoA)-mediated inhibition of free fatty acid delivery into the mitochondrion.
Mitochondrial genes included human citrate synthase (HCS), which catalyzes acetyl CoA to citrate, a key enzyme in the tricarboxylic acid cycle and a marker of mitochondrial mass [13] ; PPAR-γ coactivator-1α (PCG-1α), which is essential for mitochondrial biogenesis [14] and plays a crucial role in control of tissue-specific biological processes, coordinating it with mitochondrial oxidative metabolism; nuclear respiratory factor-1 (NRF-1), which regulates respiratory gene transcription [15] and also controls mitochondrial transcription factor-A (TFAM) [16] . TFAM binds to mtDNA and regulates its abundance, and is also responsible for the transcription of mitochondrial encoded cytochrome c oxidase (COX) subunits I, II and III [16] . PCG-1α, NRF-1 and TFAM are therefore genes closely involved with nuclear control of mitochondrial function [16] . We also measured the following mitochondrial genes: mitochondrial-encoded NADH dehydrogenase genes ND-1 and ND-4, which are involved in mitochondrial respiratory chain complex I; cytochrome B (CYT-B; complex III) and COX-3 (complex IV), both mitochondrial encoded genes involved in electron transfer; the nuclear encoded gene COX-4 (complex IV); uncoupling proteins (UCP-1, UCP-2 and UCP-3), which uncouple electron transport from ATP synthesis and protect against the accumulation of free radicals; and ATP synthase subunit 5s (ATP-5s) in complex V of the oxidative phosphorylation (OXPHOS) pathway.
Total lipase and hepatic lipase (HL) activity was measured using a fluorometric assay (Progen Biotechnik Gmbh, Heidelberg, Germany). Activities of total lipase and HL expressed as nmol free fatty acids released/ml post-heparin plasma/h were calculated from the increase in fluorescence over 15 min using a standard curve provided by the kit and a standard of known total LPL and HL activity. The activity in this standard had been determined using radioactive triolein in a glycerol-based assay with selective inhibition of LPL activity with a specific monoclonal antibody (kindly donated by JD Brunzell, University of Washington) [17] . LPL activity was assumed by subtracting HL from total lipase activity. This does not, however, take account of other potential lipases in the serum, so might be better considered as 'non-HL'.
HIV patients were tested before and 5-7 months after being randomized to treatment with either AZT/3TC/EFV or TDF/FTC/EFV. Control participants were only tested once. Categorical data were compared using Fisher's exact test. All statistical analyses on gene expression data were performed on ∆ct values and not on transformed data (AU or fold change). Comparisons between groups were made using the Mann-Whitney U test and on related samples using the Wilcoxon signedrank test. Correlations were assessed using the Spearman rank test. The P-values quoted are not corrected for multiple comparisons; however, in the tables, the results that would remain significant after a standard Bonferroni adjustment are indicated. Because the standard Bonferroni adjustment is based on an assumption of independence, this is an over-correction for these data that demonstrate substantial correlation.
Results
Patients and controls were similar in age, gender, ethnicity, weight, BMI, peripheral fat/LBM, trunk fat/LBM, VAT or SAT (Tables 1 and 2 ), family history of cardiovascular disease or diabetes. Patients randomized to the two treatment groups were also similar with regards to the above criteria, viral loads and CD4 + T-cell counts, as well as serum lipids and other biochemical characteristics (data not shown). Compared with controls, HIV patients had lower high-density lipoprotein (HDL) cholesterol (median [interquartile range (IQR)], 1.24 [1.0-1.45] and 1.4 [1.3-1.9], respectively; P=0.02) and plasma LPL activity (P=0.0001); otherwise, they were similar in all biochemical and hormonal parameters measured (data not shown). Six patients (three in each treatment group) either refused retesting (n=1) or were lost to follow-up. One patient in the AZT arm switched from EFV to Kaletra. Her results were included on the intention-to-treat analysis and her exclusion would not affect any of the results.
Serum lipid, adipocytokine and body fat changes
Following 6 months of therapy in both AZT-and TDF-treated groups, there were significant increases in serum cholesterol (P=0.009 and P=0.019, respectively), HDL cholesterol (P=0.002 and P=0.001, respectively) and in the AZT group an increase in lipoprotein(a) (P=0.008). A significant decrease in HOMA-B was also observed in both groups in comparison with pretreatment levels (P=0.008 for AZT and P=0.009 for TDF; Table 3 ). There was no significant change in weight, BMI, LBM, SAT, calculated low-density lipoprotein (LDL), triglyceride, HOMA-IR, leptin or anion gap (Tables 2 and 3 , some data not shown).
Patients randomized to AZT had lower, although non-significant, VAT and SAT estimates than those randomized to TDF (Table 2) . A significant change in body fat from baseline was seen with AZT, with an increase in VAT (P=0.02) and VAT:SAT ratio (P=0.008), these were not seen with TDF (Table 2) . There was a median gain in total body fat (peripheral fat plus trunk fat) of 1. Comparison between treatment groups for these fat gains after 6 months therapy was not significant. Serum adiponectin and leptin levels did not change significantly with either treatment.
Viral load and CD4 + T-cell counts were similar between the two groups before initiating antiretroviral treatment. Two patients, both on AZT, had detectable viral loads at 6 months (209 and 109,638 copies/ml). Both patients had undetectable viral loads at their next visit and admitted to poor compliance.
Gene expression
Gene expression levels are shown in Figures 1 and 2 and Table 4 . UCP-1 gene expression was undetectable in the majority of the first 17 samples tested and, therefore, testing for this gene was abandoned. Gene expression levels between control and HIV-infected treatmentnaive participants were broadly comparable. The only significant differences were observed with 11βHSD-1 and PPAR-γ, which were significantly under-expressed (P=0.028 and P=0.01, respectively) and CYT-B, which was over-expressed (P=0.004) in the HIV-infected treatment-naive patients compared with uninfected controls. Following 6 months of treatment in both AZT and TDF groups, there was significant up-regulation of 11βHSD-1 and PPAR-γ to levels similar to those seen in the HIVuninfected group. In the AZT group, CYT-B expression decreased significantly after 6 months of treatment to a lower level than in the controls (P=0.047). No such change was seen in the TDF-treated group in which after 6 months of treatment CYT-B remained significantly overexpressed compared with controls (P=0.03; Table 4 ).
Expressions of each gene following treatment compared with pretreatment, and also compared with controls, are given for AZT and TDF treatment groups separately (Table 4) . Figures 1 and 2 show the results in the two treatment groups as a fold-change in gene expression relative to pretreatment levels (equal to 1). In the AZT-treated patients, there was a significant increase in expression of the following genes: PPAR-γ (P=0.003), H6PDH (P=0.047), 11βHSD-1 (P=0.028), GR-α (P=0.005), FAS (P=0.028), FABP-4 (P=0.007), LPL (P=0.037), HSL (P=0.047), GLUT-4 (P=0.05), ACC-1 (P=0.033) and ACC-2 (P=0.012; Figure 1 ). The mitochondrial-encoded gene ND-4 and the nuclearencoded genes COX-4 (complex IV) and HCS were significantly up-regulated (0.012 and 0.019, respectively; P=0.008), whereas mitochondrial-encoded genes, encoding components of complex III (CYT-B; P=0.003) and complex IV (COX3; P=0.03) were significantly down-regulated (Figure 2 ). Homeostasis model of assessment for insulin resistance (HOMA-IR) =(insulin IU/l × glucose mmol/ml)/22.9, and for β-cell function (HOMA-B) =(220× insulin IU/l)/(glucose mmol/l -3.5). HDL, highdensity lipoprotein; LDL, low-density lipoprotein; NEFA, non-esterified fatty acid; NS, non-significant. .01 compared with pretreatment. c P-values indicate significant differences between zidovudine (AZT) and tenofovir disoproxil fumarate (TDF). COX, cytochrome oxidase; CYT-B, cytochrome B; HCS, human citrate synthase; NRF-1, nuclear respiratory factor-1; TFAM, mitochondrial transcription factor-A; UCP, uncoupling protein.
The changes observed in the TDF treatment group were less pronounced. Of the genes controlling cortisol and fatty acid metabolism, only PPAR-γ (P=0.002), 11βHSD-1 (P=0.05), GR-α (P=0.03), HSL (P=0.015) and ACC-2 (P=0.002) were significantly up-regulated compared with pretreatment levels. None of the mitochondrial genes were significantly different after 6 months of therapy. Overall, gene expression was significantly altered compared with pretreatment levels in 16 of the 24 genes evaluated after AZT therapy and 5 of 24 genes after TDF.
Analysis of gene expression comparing treatment groups to uninfected controls as a baseline was carried out in order to assess the effects of 6 months of ARV treatment. On the basis of this analysis, it was again noted that TDF treatment had a lesser effect on gene expression, altering expression of 6/24 genes studied, whereas AZT treatment affected 14/24 (Table 4) . Only NRF-1, TFAM, CYT-B, COX-3, HCS and FAS (P=0.04-0.001) were up-regulated by TDF treatment compared with negative controls. In the AZT-treated arm, however, PCG-1α, NRF-1, TFAM, COX-4, UCP-2, HCS, H6PDH, GR-α, FAS, FABP-4, LPL, HSL and GLUT-4 (P=0.037-0.0001) showed increased gene expression compared with controls, whereas CYT-B gene expression was reduced (P=0.047; Table 4 ).
Prior to initiation of antiretroviral therapy, there was no statistical difference between TDF and AZT treatment groups in the expression of any of the genes assayed. However, after 6 months of treatment, steadystate mRNA levels of the following genes were significantly different when the two treatment groups were compared: H6PDH (P=0.04; Figure 1 ) was significantly up-regulated for AZT, and, conversely, CYT-B (P=0.0001) and COX-3 (P=0.04) were significantly down-regulated in the AZT group compared with the TDF-treated patients (Figure 2 ). e Tenofovir disoproxil fumarate (TDF) 6 months versus baseline. f TDF 6 months versus control. g Gene expressions for nuclear respiratory factor-1 (NRF-1), peroxisome proliferator-activated receptor (PPAR)-γ coactivator-1α (PCG-1α), ND-4, uncoupling protein-3 (UCP-3) and ATP synthase subunit 5s (ATP-5s) are multiplied by 1,000.
Post-heparin plasma lipase activity
h Remains significant after Bonferroni adjustment (see text). ACC-1, acetyl coenzyme A carboxylase-1; ACC-2, acetyl coenzyme A carboxylase-2; COX, cytochrome oxidase; CYT-B, cytochrome B; FABP-4, fatty acid binding protein-4; FAS, fatty acid synthase; GLUT-4, glucose receptor-4; GR-α, glucocorticoid receptor-α; HCS, human citrate synthase; HSL, hormone-sensitive lipase; H6PDH, hexose 6-phosphate dehydrogenase; LPL, lipoprotein lipase; NS, non-significant; TFAM, mitochondrial transcription factor-A; 11βHSD-1, 11β-hydroxysteroid dehydrogenase type-1.
versus 603 nmol/ml/h [395-652]; P=0.0001). There was a small increase in LPL activity 6 months after AZT treatment (P=0.05), which was not observed with TDF. The LPL activity at 6 months remained below control levels for both treatment groups (P=0.05 for AZT and P=0.012 for TDF; Table 3 ). Compared with controls HL activity was not significantly different in the HIV-infected patients, both before (P=0.08) and after therapy in either group (P=0.295 for AZT and P=0.15 for TDF).
Correlations
Only correlations with significance ≤P=0.01 are presented. There were a number of correlations between the nuclear genes controlling mitochondrial-encoded OXPHOS genes (PCG-1α, NRF-1 and TFAM) and the mitochondrial-encoded genes (Spearman correlation ranging from 0.54 to 0.70) and also correlation of some of the mitochondrial-encoded genes with expression of a number of genes involved in the control of fatty acid and cortisol metabolism (ND-4 ρ=0.58-0.77, COX-4 ρ=0.55-0.76 and UCP-3 ρ=0.51-0.72). There was a negative correlation between CYT-B and COX-4 expression (ρ=-0.49; P=0.01).
There was strong correlation between most of the genes controlling fatty acid and cortisol metabolism and also adiponectin gene (Spearman correlation ranging from 0.51 to 0.9). For example, after 6 months of therapy 11βHSD-1 gene expression correlated with LPL, GR-α, FABP-4, ACC-1, CYT-B, COX-4 and UCP-3 genes (ρ=0.51-0.69, P=0.01-0.001). 11βHSD-1 gene expression also significantly correlated with increases in trunk fat (ρ=0.6, P=0.002). There was no correlation between regional fat accumulation and PPAR-γ or adiponectin gene expression. However, serum adiponectin levels correlated with HDL cholesterol both before (ρ=0.5, P=0.006) and after (ρ=0.58, P=0.003) antiviral treatment (ART). Serum leptin correlated with total body fat before and after ART (ρ=0.8, P=0.0001 and ρ=0.93, P=0.0001, respectively).
Discussion
Our results confirm previous reports that there were only minor differences in the expression of genes involved in adipocyte differentiation and fatty acid metabolism between HIV-infected treatment-naive patients and controls (down regulation of 11βHSD-1 and PPAR-γ) [8, 18] . However, following 6 months of ART, we observed distinct changes in patterns of gene expression compared with pretreatment levels. In AZT treated patients, markers of adipocyte differentiation and expression of key components contributing to lipid accumulation (PPAR-γ, FABP-4, ACC-1, FAS and LPL) increased. The observed increase in GLUT-4 and HCS gene expression is compatible with increased energy utilization (GLUT-4), tricarboxylic acid cycle activity and mitochondrial mass (HCS) [13] . In addition, the increased expression of ACC-2 in both AZT and TDF groups might contribute to decreased fatty acid utilization through malonyl CoA production and consequent inhibition of carnitine palmitoyltransferase 1, which transfers fatty acids across the mitochondrial membrane for β-oxidation [19] . Changes in the TDF group were in the same direction but less pronounced, with significant changes observed in only five genes (PPAR-γ, 11βHSD-1, GR-α, HSL and ACC-2; Table 4 and Figure 1) . Indeed, the up-regulation of key genes controlling adipocyte fatty acid metabolism, glucose metabolism and adipocyte differentiation were more pronounced with AZT treatment, as compared with TDF for all of the genes examined ( Figure 1 ). This was associated with a small increase in post-heparin LPL activity in the AZT group, but not the TDF group following treatment.
The up-regulation of PPAR-γ in both treatment groups might reflect its important role in adipocyte differentiation, fatty acid flux and triglyceride storage [20] . There is evidence that 11βHSD-1 is a key enzyme in adipocyte differentiation [4, 21] . Increased 11βHSD-1 and GR-α expression, observed in both groups, would act together to enhance glucocorticoid action within adipose tissue and drive adipocyte differentiation [22] . The net effect of these changes would be to promote lipid storage and limit utilization, which is supported by a trend observed in the phenotypical changes of both groups towards increased peripheral/LBM and trunk fat/LBM (significant if groups analysed together, but not when looked at individually; Table 2 ). VAT and VAT:SAT ratio were also increased following treatment in both groups, although only reaching significance in those treated with AZT. Our results are compatible with observations that report an increase in both trunk and peripheral fat 6 months after ART [5, 23, 24] , although our patients were not severely immunocompromised, did not have an AIDS-defining disease, and did not have significant weight loss before initiating ART.
Comparing the two treatment groups after 6 months of therapy, only steady-state mRNA levels in H6PDH-1 ( Figure 1) were significantly different. The overall changes in gene expression, which suggest a reduced effect of TDF on adipocyte differentiation, were also mirrored in phenotypical changes in the patients in body fat distribution with less increase in VAT and VAT:SAT ratio in the TDF group. Gene expression might not accurately reflect changes in the activity of the target proteins because of the effect of tissue-specific posttranscription regulatory factors, or post-translational modification of such factors, in regulating expression of mitochondrial OXPHOS proteins and also in the nuclear-mitochondrial response to cellular events [16] . However, the observed changes in body fat distribution wit h the two treatment regimens is compatible with the differences seen in the expression of genes involved with adipocyte differentiation and fat storage.
There were also significant differences in several key mitochondrial electron transport genes, with the AZT-treated group showing features of a disturbance in the OXPHOS complexes (Figure 1) . Key mitochondrial-encoded electron transport genes on complex III (CYT-B) were down-regulated to levels below that seen prior to treatment, as well as in control participants, and COX-3 (complex IV) was reduced compared with its pretreatment expression. The differences between the two treatment arms were significant for these two genes after 6 months of therapy. In patients on AZT, but not TDF, these changes are accompanied by what appears to be a compensatory increase in the nuclearencoded COX-4, as has been reported in vivo [25] and in vitro [26] for thymidine analogue-containing regimens. COX-4 responds directly to the nuclear gene PCG-1α, which was also up-regulated in the AZT group compared with controls, whereas mitochondrial-encoded genes respond to PCG-1α through a number of factors, including NRF-1 and TFAM [16] . TFAM was up-regulated in both HIV treatment groups compared with controls ( Table 4 ). The early mitochondrial gene ND-4, which is also under the control of TFAM [16] , was significantly up-regulated following treatment with AZT.
The changes seen in the mitochondrial genes with AZT can be categorized as a shift from aerobic to anaerobic metabolism. The up-regulation of UCP-2 in AZTtreated patients compared with controls, but not with pretreatment levels, is in keeping with increased leakage of electrons from the respiratory chain as a result of impairment of electron transport [27] . Even at low rates of respiratory impairment, an increase in reactive oxygen species can occur [28] and might be important in the early crucial events in HIV-related lipodystrophy [29] . Excessive heat loss as a consequence to increase in UCP-2 is compatible with the observed increase in resting and total energy expenditure seen in HIV-related lipodystrophy [30] . The impairment in the adipocyte electron transport chain with AZT treatment occurred despite no demonstrable peripheral fat loss, and indeed a trend towards fat gain. The small up-regulation in the nuclear gene PCG-1α cannot apparently compensate for this increased oxidative stress in the AZT-treated group, suggesting an effect of AZT on mitochondrial gene transcription [31] .
Our findings of a reduced LPL activity in both groups of treated HIV-infected patients compared with controls are consistent with previous studies [32] . We also found a significant LPL reduction in the HIV-positive treatment-naive group. LPL is the enzyme primarily responsible for triglyceride clearance from the circulation [33] and LPL deficiency in HIV-uninfected participants is associated with high triglyceride levels and low HDL cholesterol [33] , similar changes to those reported in untreated HIV infection [32] . In a previous study, we showed that in HIV-infected patients, both treatmentnaive and treatment-experienced, the triglyceride rich apolipoprotein-B100-containing lipoproteins (very low-density lipoprotein, intermediate-density lipoprotein and LDL), synthesised by the liver, have longer residence time in circulation [34, 35] . The significant reduction in LPL activity provides an explanation for these findings and could also contribute to the low HDL cholesterol seen in the HIV-infected patients through the activity of cholesterol ester transfer protein.
Adiponectin levels increased following treatment, despite a small increase in trunk and peripheral fat (0.52 and 0.46 kg, respectively), which is opposite of the effect expected from a HIV-uninfected population [36] . Utilizing the same assay and methodology we had previously reported, reduced adiponectin levels in treatment-naive and treatment-experienced HIV-infected patients compared with controls [37] . The reason for the difference observed between the two studies is unclear; however, in the case of HIV-infected treated patients this might reflect the different duration of therapy. We did, however, confirm our previous finding of a correlation of HDL cholesterol and adiponectin levels [37] .
Earlier studies on the mechanism of lipodystrophy following ART have implicated reductions in mtDNA caused by interference of nucleoside analogues with mtDNA polymerase-γ [4, 7, 8, 38, 39] . However, abnormalities in mitochondrial-encoded respiratory complex genes and disturbances in cellular metabolism can also be shown in the absence of demonstrable reduction in mtDNA both in HIV-infected treatment-naive patients [40] , in patients with lipodystrophy [41] and in HIVnegative patients [31] . Unlike stavudine [42] , AZT produced less, if any, mtDNA loss [8, 43, 44] and the effect could be predominantly mediated through other mechanisms, such as interference with both nuclear and mitochondrial-encoded respiratory gene expression and oxidative function in the adipocyte [8, 9, 31, 42] , as well as other tissues.
The majority of clinical studies examining the effects of ART on adipocyte metabolic and mitochondrial respiratory genes are cross-sectional [8, 39, [44] [45] [46] [47] and many have been conducted on patients who have been on treatment for many years or have clinical lipodystrophy. Differences between our results and those reported by others [41, 45] could relate to differences in gender and ethnic origin, use of protease inhibitors, longer time on treatment [8, 41, 45] , use of HIV-negative participants given short courses of dual nucleoside analogues [31] and possible depot-specific differences with regard to site of subcutaneous fat biopsies [24, 48] .
Our results confirm previous reports of a central role for adipocyte cortisol generation and adipocyte differentiation, for which glucocorticoid is an essential requirement [22] . 11βHSD-1 is a key gene in adipocyte differentiation [4, 21] and, by increasing intracellular glucocorticoid exposure of VAT, has been implicated in the metabolic syndrome in both HIV-uninfected individuals [49] and in HIV-infected patients with lipodystrophy [50] . A number of studies have reported an increased incidence of metabolic syndrome after ART [51, 52] . In a prospective study, Kratz et al. [24] showed a reduction in 11βHSD-1 mRNA concentration in both thigh and abdominal SAT in patients who later developed lipoatrophy, but before clinical evidence of peripheral fat loss. The expression of 11βHSD-1 also differed substantially between abdominal and thigh SAT [24] . Our study showed up-regulation of the 11βHSD-1 gene and, additionally, in patients on AZT, an up-regulation of the cofactor H6PDH in subcutaneous adipocytes obtained from the iliac crest 6 months after treatment. We also showed a close correlation between the expression of 11βHSD-1 gene, but not PPAR-γ, adiponectin and leptin genes (which are also associated with adipocyte differentiation) and increases in trunk fat. Should VAT behave in the same way as our subcutaneous adipocyte samples, as has been suggested [48] , then persistence of such up-regulation of adipocyte differentiation genes in some patients could explain the increased incidence of the metabolic syndrome following ART [51, 52] .
Our study has shown that HIV-infected treatmentnaive patients have significantly reduced plasma LPL activity and a reduction in key adipocyte differentiation genes 11βHSD-1 and PPAR-γ. After 6 months of ART there is an up-regulation of key genes involved with adipocyte differentiation compatible with the 'return to health' of the patients reported in many cohort studies. However, already at this early stage of treatment, AZT but not TDF-containing regimens show a disturbance in the mitochondrial electron transport chain. The upregulation in adipocyte glucocorticoid and fatty acid metabolism, and genes controlling adipocyte differentiation and lipid storage are also more marked with AZT. Should such up-regulation of adipocyte differentiation be reflected in VAT, its persistence over the next few years in some patients might explain the increase in the incidence and prevalence of metabolic syndrome reported in many studies. To investigate this hypothesis, we are planning to retest the patients 18-24 months into ART.
